Loading
A phase 3 trial of toripalimab and anlotinib in lung cancer, run by Taizhou Hospital, not yet recruiting.
Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell is a phase 3, randomised interventional study registered as NCT06441344 by Taizhou Hospital, with a registry enrolment figure of 136 participants, started 2024-07-01 and due to reach its primary completion in 2026-05-01. Interventions recorded: Toripalimab plus Anlotinib; Toripalimab. Conditions listed: SCLC; Maintenance Treatment. Primary outcome: progression free survival(PFS); overal survival time(OS). Lung eligibility wording from the registry: "* Confirmed as small cell lung cancer (SCLC) by histopathology or cytology and diagnosed as extensive after systemic evaluation". No results are recorded here; the registry entry is the source.
Shares Anlotinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Anlotinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Anlotinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Anlotinib, Extensive-stage small-cell lung cancer, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Anlotinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Anlotinib, Extensive-stage small-cell lung cancer, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Anlotinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.